Taysha Gene Therapies Posts Wider-Than-Expected GAAP Loss of $0.12 Per Share
The biotech firm's quarterly loss exceeded analyst estimates by $0.02, signaling higher-than-anticipated costs. Taysha Gene Therapies reported a GAAP loss of $0.12 per share for the quarter, missing expectations by $0.02. The wider loss reflects increased research and deve